Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 19/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.67 |
| ▸ | BACE2 | Q9Y5Z0 | 11/20 | 0.46 |
| ▸ | CTSD | P07339 | 7/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL2086620 | 0.89 | BACE1 (0.55) | BACE1KCNH2BACE2CTSDNPSR1 | |
| SCHEMBL3782717 | 0.88 | BACE1 (0.56) | BACE1KCNH2BACE2CTSD | |
| SCHEMBL2086983 | 0.85 | BACE1 (0.51) | BACE1KCNH2BACE2NPSR1 | |
| SCHEMBL2084817 | 0.85 | BACE1 (0.50) | BACE1KCNH2BACE2CTSD | |
| SCHEMBL2086521 | 0.85 | BACE1 (0.50) | BACE1KCNH2BACE2CTSDNPSR1 | |
| SCHEMBL2084961 | 0.85 | BACE1 (0.50) | BACE1KCNH2BACE2NPSR1 | |
| SCHEMBL2085746 | 0.85 | BACE1 (0.50) | BACE1KCNH2BACE2CTSD | |
| SCHEMBL2082796 | 0.83 | BACE1 (0.51) | BACE1KCNH2BACE2CTSDNPSR1 | |
| SCHEMBL2085844 | 0.83 | BACE1 (0.52) | BACE1KCNH2BACE2CTSD | |
| SCHEMBL2087801 | 0.83 | BACE1 (0.47) | BACE1KCNH2BACE2CTSDNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101506162-B | Substituted isoindoles as bace inhibitors and their use | ASTRAZENECA AB | 2012-06-27 | — | — | CN | disclosed |
| US-20110059992-A1 | New Compounds | ASTRAZENECA AB (SE) | 2011-03-10 | — | — | US | disclosed |
| US-20110059992-A1 | New Compounds | ASTRAZENECA AB (SE) | 2011-03-10 | — | — | US | disclosed |
| US-20110059992-A1 | New Compounds | ASTRAZENECA AB (SE) | 2011-03-10 | — | — | US | disclosed |
| US-7855213-B2 | Compounds | ASTRAZENECA AB (SE) | 2010-12-21 | — | — | US | disclosed |
| US-7855213-B2 | Compounds | ASTRAZENECA AB (SE) | 2010-12-21 | — | — | US | disclosed |
| US-7855213-B2 | Compounds | ASTRAZENECA AB (SE) | 2010-12-21 | — | — | US | disclosed |
| CN-101506162-A | Substituted isoindoles as bace inhibitors and their use | ASTRAZENECA AB (SE) | 2009-08-12 | — | — | CN | disclosed |
| EP-2035378-A1 | SUBSTITUTED ISOINDOLES AS BACE INHIBITORS AND THEIR USE | AstraZeneca AB (SE) | 2009-03-18 | — | — | EP | disclosed |
| US-20080171771-A1 | New Compounds 391 | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| US-20080171771-A1 | New Compounds 391 | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| US-20080171771-A1 | New Compounds 391 | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| WO-2007149033-A1 | SUBSTITUTED ISOINDOLES AS BACE INHIBITORS AND THEIR USE | ASTRAZENECA AB (SE) | 2007-12-27 | — | — | WO | disclosed |
| WO-2007149033-A1 | SUBSTITUTED ISOINDOLES AS BACE INHIBITORS AND THEIR USE | ASTRAZENECA AB (SE) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059992-A1 | New Compounds | MAPT, PSEN2, PSEN1 | BACE1 5/4885KCNH2 3126/4885BACE2 18/4885 |
| US-20080171771-A1 | New Compounds 391 | PSEN2, PSEN1, MAPT | BACE1 4/4885KCNH2 2710/4885BACE2 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.